PortfoliosLab logoPortfoliosLab logo
OCUL vs. ANIP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

OCUL vs. ANIP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ocular Therapeutix, Inc. (OCUL) and ANI Pharmaceuticals, Inc. (ANIP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, OCUL achieves a -16.68% return, which is significantly lower than ANIP's 5.07% return. Over the past 10 years, OCUL has outperformed ANIP with an annualized return of 6.94%, while ANIP has yielded a comparatively lower 4.32% annualized return.


OCUL

1D
1.45%
1M
22.90%
YTD
-16.68%
6M
-20.60%
1Y
20.85%
3Y*
27.59%
5Y*
-7.12%
10Y*
6.94%

ANIP

1D
2.93%
1M
0.27%
YTD
5.07%
6M
2.74%
1Y
25.61%
3Y*
17.04%
5Y*
19.79%
10Y*
4.32%
*Multi-year figures are annualized to reflect compound growth (CAGR)

OCUL vs. ANIP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
OCUL
Ocular Therapeutix, Inc.
-16.68%42.15%91.48%58.72%-59.68%-66.33%424.05%-0.75%-10.56%-46.83%
ANIP
ANI Pharmaceuticals, Inc.
5.07%42.80%0.25%37.06%-12.70%58.68%-52.91%36.98%-30.15%6.32%

Correlation

The correlation between OCUL and ANIP is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (10Y)
Calculated over the trailing 10-year period

0.31

Correlation (All Time)
Calculated using the full available price history since Jul 25, 2014

0.31

The correlation between OCUL and ANIP shifts across timeframes, from 0.20 (1 year) to 0.33 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

OCUL:

$2.27B

ANIP:

$1.79B

EPS

OCUL:

-$1.45

ANIP:

$4.26

PS Ratio

OCUL:

39.05

ANIP:

1.89

PB Ratio

OCUL:

3.90

ANIP:

3.18

Total Revenue (TTM)

OCUL:

$52.04M

ANIP:

$923.71M

Gross Profit (TTM)

OCUL:

$45.40M

ANIP:

$486.11M

EBITDA (TTM)

OCUL:

-$283.03M

ANIP:

$234.71M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

OCUL vs. ANIP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OCUL
OCUL Risk / Return Rank: 5353
Overall Rank
OCUL Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
OCUL Sortino Ratio Rank: 5656
Sortino Ratio Rank
OCUL Omega Ratio Rank: 5555
Omega Ratio Rank
OCUL Calmar Ratio Rank: 5252
Calmar Ratio Rank
OCUL Martin Ratio Rank: 5050
Martin Ratio Rank

ANIP
ANIP Risk / Return Rank: 6363
Overall Rank
ANIP Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
ANIP Sortino Ratio Rank: 6565
Sortino Ratio Rank
ANIP Omega Ratio Rank: 6161
Omega Ratio Rank
ANIP Calmar Ratio Rank: 6262
Calmar Ratio Rank
ANIP Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OCUL vs. ANIP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ocular Therapeutix, Inc. (OCUL) and ANI Pharmaceuticals, Inc. (ANIP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


OCULANIPDifference
Sharpe ratioReturn per unit of total volatility

-0.42

Sortino ratioReturn per unit of downside risk

-0.42

Omega ratioGain probability vs. loss probability

1.12

1.16

-0.04

Calmar ratioReturn relative to maximum drawdown

0.37

0.90

-0.53

Martin ratioReturn relative to average drawdown

0.68

1.65

-0.96

OCUL vs. ANIP - Sharpe Ratio Comparison

The current OCUL Sharpe Ratio is 0.30, which is lower than the ANIP Sharpe Ratio of 0.72. The chart below compares the historical Sharpe Ratios of OCUL and ANIP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

OCUL vs. ANIP - Drawdown Comparison

The maximum OCUL drawdown since its inception was -95.19%, roughly equal to the maximum ANIP drawdown of -98.81%. Use the drawdown chart below to compare losses from any high point for OCUL and ANIP.


Loading charts...

Drawdown Indicators


OCULANIPDifference

Max Drawdown

Largest peak-to-trough decline

-95.19%

-98.81%

+3.62%

Max Drawdown (1Y)

Largest decline over 1 year

-57.29%

-28.66%

-28.63%

Max Drawdown (3Y)

Largest decline over 3 years

-61.57%

-28.66%

-32.91%

Max Drawdown (5Y)

Largest decline over 5 years

-85.50%

-59.38%

-26.12%

Max Drawdown (10Y)

Largest decline over 10 years

-90.94%

-72.96%

-17.98%

Current Drawdown

Current decline from peak

-76.62%

-81.57%

+4.95%

Average Drawdown

Average peak-to-trough decline

-76.60%

-79.39%

+2.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.54%

15.57%

+14.97%

Volatility

OCUL vs. ANIP - Volatility Comparison

Ocular Therapeutix, Inc. (OCUL) has a higher volatility of 17.41% compared to ANI Pharmaceuticals, Inc. (ANIP) at 9.49%. This indicates that OCUL's price experiences larger fluctuations and is considered to be riskier than ANIP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


OCULANIPDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.41%

9.49%

+7.92%

Volatility (6M)

Calculated over the trailing 6-month period

54.37%

24.64%

+29.73%

Volatility (1Y)

Calculated over the trailing 1-year period

70.06%

35.64%

+34.42%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

78.53%

46.34%

+32.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.83%

48.19%

+30.64%

Dividends

OCUL vs. ANIP - Dividend Comparison

Neither OCUL nor ANIP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

OCUL vs. ANIP - Financials Comparison

This section allows you to compare key financial metrics between Ocular Therapeutix, Inc. and ANI Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M20222023202420252026
10.79M
237.46M
(OCUL) Total Revenue
(ANIP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


OCUL and ANIP have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OCUL has higher volatility (17.41%) compared to ANIP (9.49%). In terms of maximum drawdown, OCUL dropped -95.19% vs ANIP's -98.81%.

ANIP currently has the higher Sharpe Ratio (0.72 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for OCUL and ANIP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer